Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days.

Accolade To Present at Upcoming Investor Conferences

TORONTO--(BUSINESS WIRE)--Porter Airlines has been rated a 2025 Four Star Major Airline by passengers, certified by the Airline Passenger Experience Association (APEX). The APEX Five Star and Four Star Airlines Awards are the only global awards based entirely on neutral, third-party passenger feedback. They are a result of passenger ratings of almost one million flights across nearly 600 airlines around the world, certified by APEX in partnership with TripIt® from Concur®. “Receiving this ratin.

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD).  SEATTLE , Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions.

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accolade (ACCD) Upgraded to Buy: Here's What You Should Know

Accolade, Inc. (NASDAQ:ACCD ) Q2 2025 Earnings Conference Call October 8, 2024 8:00 AM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Jeff Garro - Stephens Inc. Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jared Haase - William Blair Stephanie Davis - Barclays Allen Lutz - Bank of America Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Operator Ladies and gentlemen, thank you for standing by. Welcome to Accolade Second Quarter 2025 Earnings Results Conference Call.

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.

Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates

On October 8, 2024, Accolade Inc (ACCD, Financial) released its 8-K filing detailing the financial results for the fiscal second quarter ending August 31, 2024. Accolade Inc, a company offering technology-enabled solutions to navigate the healthcare system, reported a revenue of $106.4 million, exceeding the analyst estimate of $105.01 million.

Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024.

Accolade Announces Results for Fiscal Second Quarter 2025

Accolade Inc (ACCD, Financial) is set to release its Q2 2025 earnings on Oct 8, 2024. The consensus estimate for Q2 2025 revenue is $105.01 million, and the earnings are expected to come in at -$0.44 per share.

Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings

Accolade, Inc. ACCD will release earnings results for its second quarter, before the opening bell on Tuesday, Oct. 8.

Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings

SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day.

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Accolade (ACCD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Accolade (ACCD) Rating Upgrade to Buy

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Accolade, Inc. (ACCD)

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET.

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Accolade, Inc. (ACCD) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Accolade, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ACCD

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Accolade, Inc. (ACCD) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Accolade Being Investigated on Behalf of Accolade, Inc. Investors. Contact Levi & Korsinsky For Details.

LITTLE ROCK, Ark. , Aug. 22, 2024 /PRNewswire/ -- Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers.

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Accolade, Inc. (ACCD) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Lost Money on Accolade, Inc.(ACCD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Did Accolade, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ACCD

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

Lost Money on Accolade, Inc.(ACCD)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.

News for Accolade Stock (ACCD)